Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Susan Jones

Physician Assistant, Medical Longview, TX Physician Assistant

NPI 1265457741 CMS profile 10915834

703 E Marshall Ave, Suite 1001, Longview, TX 75601

Open in the dashboard

General payments

$16,347

654 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Susan Jones of Longview, TX is reported in the CMS Open Payments database as having received $16,347 across 654 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,431 135
2024 General $3,318 145
2023 General $4,997 197
2022 General $2,926 112
2021 General $1,675 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Jones
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Susan Jones were reported at $3,431. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Susan Jones Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,675 $156 $41–$563 $132
2022 $2,926 $185 $55–$649 $149
2023 $4,997 $199 $58–$717 $160
2024 $3,318 $206 $62–$740 $164
2025 $3,431 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $6,453 252 payments
  2. Amgen Inc. $2,633 106 payments
  3. AstraZeneca Pharmaceuticals LP $1,522 49 payments
  4. Lilly USA, LLC $822 39 payments
  5. UCB, Inc. $812 24 payments
  6. GlaxoSmithKline, LLC. $741 34 payments
  7. Radius Health, Inc. $436 19 payments
  8. Janssen Biotech, Inc. $350 15 payments
  9. Aurinia Pharma U.S., Inc. $305 9 payments
  10. Mallinckrodt Hospital Products Inc. $281 8 payments
  11. Other $1,992 99 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,280 653 payments
  2. Education $67 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $4,894 196 payments
  2. SKYRIZI Immunology $1,862 69 payments
  3. Otezla $1,019 40 payments
  4. TALTZ $822 39 payments
  5. SAPHNELO $765 28 payments
  6. Enbrel Inflammation $748 43 payments
  7. SKYRIZI Immunology $702 27 payments
  8. Enbrel Inflammation $650 24 payments
  9. Cimzia $501 15 payments
  10. FASENRA $496 11 payments
  11. Other $7,230 286 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

4,825

Median for Physician Assistant: 241

Drug cost

$1,914,352

Median for Physician Assistant: $4,110

Branded share of claims

17.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 86 $587,499
Enbrel Sureclick Etanercept Brand 61 $476,936
Rinvoq Upadacitinib Brand 63 $399,266
Enbrel Mini Etanercept Brand 28 $206,196
Cimzia (2 Pack) Certolizumab Pegol Brand 14 $85,366
Otezla Apremilast Brand 16 $76,118
Sulfasalazine Generic 519 $14,451
Hydroxychloroquine Sulfate Generic 458 $12,114
Methotrexate Methotrexate Sodium Brand 539 $11,406
Leflunomide Generic 281 $9,437

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $1,176
$1,176 63 —
SKYRIZI
  • AbbVie, Inc. $606
$606 — —
Otezla
  • Amgen Inc. $330
$330 16 —
EVENITY
  • Amgen Inc. $174
$174 — —
TALTZ
  • Lilly USA, LLC $174
$174 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

654 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record